Phio Pharmaceuticals Corp. PHIO 深 滬
等待開盤 08-21 09:30:00 美东时间
1.21
+0.060
+5.22%
華盛通- 最 高1.22
- 今 開1.16
- 成交量 33.29万股
- 最 低 1.10
- 昨 收 1.15
- 總市值 1.41万
- 52周最高 4.1899
- 市盈率 靜 --
- 換手率 2865.18%
- 52周最低 0.8127
- 委 比 -99.34%
- 總股本 1.16万
- 歷史最高 3118.50
- 量 比 1.78
- 振 幅 10.43%
- 歷史最低 0.8127
- 每 手 1
- 風險率 0.44%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Phio Pharma To Discuss siRNA Oncology At Force Family Office Fireside Chat; INTASYL Program Positioned As Differentiated Immuno‑Oncology Strategy
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will ...
06-25 19:19
Phio Pharma Q1 EPS $(0.34) Misses $(0.23) Estimate
Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.23) by 47.83 percent. This is a 27.66 percent increase over losses of $(0.47) per share from the
05-08 04:51
Phio Pharmaceuticals Enters Into A cGMP Drug Product Manufacturing Services Agreement With A US Manufacturer For Its Lead Compound, Ph-762, For Both Clinical Trial And Commercial Supply
Recent Company Highlights Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy for cutaneous carcinomas. In its Phase 1b trial, Phio has reported that 22 patients completed treatment
03-30 19:22
Phio Pharmaceuticals Announces Positive Clinical Data Supporting Treatment Research For Specific Carcinomas, To Be Presented March 28th
The presentation, entitled "PD-1 Directed Intratumoral Immunotherapy: Results of an Escalating Dose Study of INTASYL PH-762 for Cutaneous Carcinomas", will highlight results of Phio's Phase 1b clinical study (NCT
03-23 19:17
